Chronic Pancreatitis (CP) Market Report 2026

The chronic pancreatitis (cp) market size has grown strongly in recent years. It will grow from $5.23 billion in 2025 to $5.56 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to improved diagnostic imaging availability, increased awareness of pancreatic disorders, wider use of pain management therapies, expansion of gastroenterology services, improved supportive care options.

The chronic pancreatitis (cp) market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing development of advanced enzyme formulations, rising focus on early-stage intervention, expansion of outpatient treatment models, growing integration of nutrition-based therapies, increasing investment in pancreatic disease research. Major trends in the forecast period include increasing use of enzyme replacement therapies, rising adoption of minimally invasive endoscopic treatments, growing focus on nutritional management, expansion of personalized treatment plans, enhanced emphasis on early diagnosis.

The increasing consumption of alcohol is expected to drive the growth of the chronic pancreatitis market in the coming years. Alcohol consumption refers to the intake of beverages containing ethanol, often for recreational, social, or cultural reasons, but excessive intake can result in dependency and significant health risks. Rising alcohol consumption is influenced by factors such as greater social acceptance, urbanization, evolving lifestyles, and stress management practices, particularly among younger populations. Alcohol contributes to chronic pancreatitis by causing inflammation and damage to pancreatic cells, leading to fibrosis, ductal obstruction, and long-term pancreatic dysfunction due to toxic metabolic byproducts. For instance, in 2025, according to the Priory Group, a UK-based provider of mental health, addiction, and specialist education services, a 2023 survey reported that 25% of individuals aged 18 to 24 in the UK now abstain completely from alcohol, indicating a notable shift toward sobriety among younger people. Therefore, increasing alcohol consumption is contributing to the growth of the chronic pancreatitis market.

Major companies operating in the chronic pancreatitis market are concentrating on technological advancements such as enzyme replacement therapy to address exocrine pancreatic insufficiency associated with chronic pancreatitis. Enzyme replacement therapy involves the oral administration of pancreatic enzymes to support digestion in patients with reduced pancreatic function. For example, in July 2023, First Wave BioPharma Inc., a US-based clinical-stage biopharmaceutical company, announced results from its Phase 2 SPAN clinical trial evaluating an enhanced enteric microgranule delivery formulation of adrulipase for treating exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. Adrulipase is a recombinant lipase enzyme derived from the yeast Yarrowia lipolytica and is administered as an oral, non-systemic biologic capsule designed to break down fat molecules in the digestive tract, enabling nutrient absorption in patients with exocrine pancreatic insufficiency.

In March 2023, CalciMedica Inc., a US-based clinical-stage biopharmaceutical company, merged with Graybug Vision Inc. for an undisclosed amount. This merger, structured as a reverse transaction, enables CalciMedica to strengthen its focus on developing therapies for life-threatening inflammatory diseases. Graybug Vision Inc. is a US-based clinical-stage biopharmaceutical company engaged in the development of treatments for severe inflammatory conditions, including pancreatitis.

Major companies operating in the chronic pancreatitis (cp) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy's Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, Akron Biotech.

North America was the largest region in the chronic pancreatitis (CP) market in 2025. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic pancreatitis (cp) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chronic pancreatitis market by increasing costs of imported diagnostic imaging equipment, pharmaceutical ingredients, enzyme formulations, and endoscopic devices. Healthcare providers in North America and Europe are most affected due to reliance on imported medical technologies, while Asia-Pacific faces pricing pressure on drug manufacturing and equipment supply. These tariffs are contributing to higher treatment costs and delayed equipment upgrades. However, they are also encouraging domestic pharmaceutical production, localized medical device manufacturing, and regional innovation in cost-effective treatment solutions.

The chronic pancreatitis (cp) market research report is one of a series of new reports that provides chronic pancreatitis (cp) market statistics, including chronic pancreatitis (cp) industry global market size, regional shares, competitors with a chronic pancreatitis (cp) market share, detailed chronic pancreatitis (cp) market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pancreatitis (cp) industry. This chronic pancreatitis (cp) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic pancreatitis (CP) is a long-term, progressive inflammatory disorder of the pancreas that results in permanent damage to its structure and function. The condition is characterized by ongoing inflammation, fibrosis or scarring, and the gradual loss of the pancreas’s ability to produce digestive enzymes and hormones such as insulin.

The primary treatment types for chronic pancreatitis (CP) include analgesics, artificial digestive enzymes, protein supplements, steroids, antibiotics, and others. Analgesics are drugs used to manage pain, which is a common symptom associated with chronic pancreatitis. Diagnosis typically involves computed tomography (CT) scans, magnetic resonance cholangiopancreatography, ultrasound sonography, and other methods, while the routes of administration include oral and parenteral. These treatments are used by various end users such as hospitals, home care settings, and others.

The chronic pancreatitis market consists of revenues earned by entities by providing services such as diagnostic imaging, endoscopic procedures, pain management, nutritional counseling, and telemedicine services for the diagnosis and management of chronic pancreatitis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pancreatitis market also includes sales of enzyme replacement therapies, pain management drugs, anti-inflammatory treatments, biologics, stem cell therapies, and surgical interventions, as well as diagnostic tools such as imaging and laboratory tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.